Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score

Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) has intracranial activity in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC). The optimal timing of brain radiotherapy (RT) and appropriate patients who need early brain RT remains undetermined. This is a retrospective study of EGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yongmei, Deng, Lei, Zhou, Xiaojuan, Gong, Youling, Xu, Yong, Zhou, Lin, Wan, Jin, Zou, Bingwen, Wang, Yongsheng, Zhu, Jiang, Ding, Zhenyu, Peng, Feng, Huang, Meijuan, Ren, Li, Lautenschlaeger, Tim, Kong, Feng-Ming (Spring), Lu, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762323/
https://www.ncbi.nlm.nih.gov/pubmed/29340055
http://dx.doi.org/10.18632/oncotarget.22785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762323/
https://www.ncbi.nlm.nih.gov/pubmed/29340055
http://dx.doi.org/10.18632/oncotarget.22785

Ejemplares similares